The protein kinase c inhibitor aeb071 (sotrastaurin) modulates migration and superoxide anion production by human neutrophils in vitro

F. Capsoni, A. M. Ongari, E. Reali, F. Bosè, G. F. Altomare

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

We examined the effect of the protein kinase C-selective inhibitor AEB071 (sotrastaurin) on neutrophil functions in vitro. Pre-incubation with AEB071 at concentrations similar to those reached during in vivo therapy significantly reduced cell capacity to migrate toward three different chemo-attractants and to produce superoxide anions (O2) in response to phorbol myristate acetate (PMA) or to ./V-formylmethionyl-leucyl-phenylalanine (fMLP). AEB071 also significantly inhibited the O2" overproduction induced by fMLP in neutrophils primed with tumor necrosis factor alpha (TNF-α) or granulocyte/ macrophage-colony stimulating factor (GM-CSF). This inhibition was not linked to fMLP-receptor down-regulation since the drug had no effect on either fMLP-receptors or fMLP-induced CDlIb membrane expression. When the activity of AEB071 was compared to that of the conventional protein kinase C (PKC) inhibitor GÖ6850 (which, like sotrastaurin, inhibits classical and novel PKC isoforms), GÖ6976 (an inhibitor of a and β PKC isoforms) and rottlerin (a prevailing δ PKC isoform inhibitor), AEB071 at an equimolar concentration of 3 μM (close to the maximum drug concentration reached in patients treated with AEB071) caused significantly more inhibition on both chemotactic response and superoxide production. These in vitro findings suggest that neutrophils may offer a cellular target for AEB071 activity in vivo.

Original languageEnglish
Pages (from-to)617-626
Number of pages10
JournalInternational Journal of Immunopathology and Pharmacology
Volume25
Issue number3
Publication statusPublished - Jul 2012

Fingerprint

Protein Kinase Inhibitors
Superoxides
Neutrophils
N-Formylmethionine Leucyl-Phenylalanine
Protein Kinase C
Protein Isoforms
In Vitro Techniques
sotrastaurin
Protein C Inhibitor
Tetradecanoylphorbol Acetate
Granulocyte-Macrophage Colony-Stimulating Factor
Pharmaceutical Preparations
Down-Regulation
Tumor Necrosis Factor-alpha
Membranes

Keywords

  • Chemotaxis
  • Inflammation
  • Oxygen radicals
  • Phagocytes

ASJC Scopus subject areas

  • Pharmacology
  • Immunology
  • Immunology and Allergy

Cite this

The protein kinase c inhibitor aeb071 (sotrastaurin) modulates migration and superoxide anion production by human neutrophils in vitro. / Capsoni, F.; Ongari, A. M.; Reali, E.; Bosè, F.; Altomare, G. F.

In: International Journal of Immunopathology and Pharmacology, Vol. 25, No. 3, 07.2012, p. 617-626.

Research output: Contribution to journalArticle

@article{66f809013cb04b0db468a7a8af0f3876,
title = "The protein kinase c inhibitor aeb071 (sotrastaurin) modulates migration and superoxide anion production by human neutrophils in vitro",
abstract = "We examined the effect of the protein kinase C-selective inhibitor AEB071 (sotrastaurin) on neutrophil functions in vitro. Pre-incubation with AEB071 at concentrations similar to those reached during in vivo therapy significantly reduced cell capacity to migrate toward three different chemo-attractants and to produce superoxide anions (O2) in response to phorbol myristate acetate (PMA) or to ./V-formylmethionyl-leucyl-phenylalanine (fMLP). AEB071 also significantly inhibited the O2{"} overproduction induced by fMLP in neutrophils primed with tumor necrosis factor alpha (TNF-α) or granulocyte/ macrophage-colony stimulating factor (GM-CSF). This inhibition was not linked to fMLP-receptor down-regulation since the drug had no effect on either fMLP-receptors or fMLP-induced CDlIb membrane expression. When the activity of AEB071 was compared to that of the conventional protein kinase C (PKC) inhibitor G{\"O}6850 (which, like sotrastaurin, inhibits classical and novel PKC isoforms), G{\"O}6976 (an inhibitor of a and β PKC isoforms) and rottlerin (a prevailing δ PKC isoform inhibitor), AEB071 at an equimolar concentration of 3 μM (close to the maximum drug concentration reached in patients treated with AEB071) caused significantly more inhibition on both chemotactic response and superoxide production. These in vitro findings suggest that neutrophils may offer a cellular target for AEB071 activity in vivo.",
keywords = "Chemotaxis, Inflammation, Oxygen radicals, Phagocytes",
author = "F. Capsoni and Ongari, {A. M.} and E. Reali and F. Bos{\`e} and Altomare, {G. F.}",
year = "2012",
month = "7",
language = "English",
volume = "25",
pages = "617--626",
journal = "International Journal of Immunopathology and Pharmacology",
issn = "0394-6320",
publisher = "Biomedical Research Press s.a.s.",
number = "3",

}

TY - JOUR

T1 - The protein kinase c inhibitor aeb071 (sotrastaurin) modulates migration and superoxide anion production by human neutrophils in vitro

AU - Capsoni, F.

AU - Ongari, A. M.

AU - Reali, E.

AU - Bosè, F.

AU - Altomare, G. F.

PY - 2012/7

Y1 - 2012/7

N2 - We examined the effect of the protein kinase C-selective inhibitor AEB071 (sotrastaurin) on neutrophil functions in vitro. Pre-incubation with AEB071 at concentrations similar to those reached during in vivo therapy significantly reduced cell capacity to migrate toward three different chemo-attractants and to produce superoxide anions (O2) in response to phorbol myristate acetate (PMA) or to ./V-formylmethionyl-leucyl-phenylalanine (fMLP). AEB071 also significantly inhibited the O2" overproduction induced by fMLP in neutrophils primed with tumor necrosis factor alpha (TNF-α) or granulocyte/ macrophage-colony stimulating factor (GM-CSF). This inhibition was not linked to fMLP-receptor down-regulation since the drug had no effect on either fMLP-receptors or fMLP-induced CDlIb membrane expression. When the activity of AEB071 was compared to that of the conventional protein kinase C (PKC) inhibitor GÖ6850 (which, like sotrastaurin, inhibits classical and novel PKC isoforms), GÖ6976 (an inhibitor of a and β PKC isoforms) and rottlerin (a prevailing δ PKC isoform inhibitor), AEB071 at an equimolar concentration of 3 μM (close to the maximum drug concentration reached in patients treated with AEB071) caused significantly more inhibition on both chemotactic response and superoxide production. These in vitro findings suggest that neutrophils may offer a cellular target for AEB071 activity in vivo.

AB - We examined the effect of the protein kinase C-selective inhibitor AEB071 (sotrastaurin) on neutrophil functions in vitro. Pre-incubation with AEB071 at concentrations similar to those reached during in vivo therapy significantly reduced cell capacity to migrate toward three different chemo-attractants and to produce superoxide anions (O2) in response to phorbol myristate acetate (PMA) or to ./V-formylmethionyl-leucyl-phenylalanine (fMLP). AEB071 also significantly inhibited the O2" overproduction induced by fMLP in neutrophils primed with tumor necrosis factor alpha (TNF-α) or granulocyte/ macrophage-colony stimulating factor (GM-CSF). This inhibition was not linked to fMLP-receptor down-regulation since the drug had no effect on either fMLP-receptors or fMLP-induced CDlIb membrane expression. When the activity of AEB071 was compared to that of the conventional protein kinase C (PKC) inhibitor GÖ6850 (which, like sotrastaurin, inhibits classical and novel PKC isoforms), GÖ6976 (an inhibitor of a and β PKC isoforms) and rottlerin (a prevailing δ PKC isoform inhibitor), AEB071 at an equimolar concentration of 3 μM (close to the maximum drug concentration reached in patients treated with AEB071) caused significantly more inhibition on both chemotactic response and superoxide production. These in vitro findings suggest that neutrophils may offer a cellular target for AEB071 activity in vivo.

KW - Chemotaxis

KW - Inflammation

KW - Oxygen radicals

KW - Phagocytes

UR - http://www.scopus.com/inward/record.url?scp=84868033104&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868033104&partnerID=8YFLogxK

M3 - Article

C2 - 23058012

AN - SCOPUS:84868033104

VL - 25

SP - 617

EP - 626

JO - International Journal of Immunopathology and Pharmacology

JF - International Journal of Immunopathology and Pharmacology

SN - 0394-6320

IS - 3

ER -